Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beijing Normal Univ. FAP compound [99mTc]Tc-L1: sourced facts only. name: "A nanomolar Kd value for [99mTc]Tc-L1 indicates its significantly high target affinity for FAP." [PMID:36972467]; target: "A nanomolar Kd value for [99mTc]Tc-L1 indicates its significantly high target affinity for FAP." [PMID:36972467]; developer: "Key Laboratory of Radiopharmaceuticals of the Ministry of Education, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China." [PMID:36972467]; modality: "Two stable hydrophilic 99mTc-labeled complexes ([99mTc]Tc-L1 and [99mTc]Tc-L2) were obtained." [PMID:36972467]; stage: "The biodistribution and microSPECT/CT images obtained for U87MG tumor mice show that [99mTc]Tc-L1 has high tumor uptake with specificity to FAP and high tumor-to-nontarget ratios." [PMID:36972467]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Beijing Normal Univ. FAP compound [99mTc]Tc-L1.